Immunome (IMNM) Expected to Announce Earnings on Wednesday

Immunome (NASDAQ:IMNM) will likely be posting its Q4 2025 results before the market opens on Wednesday, March 18th. Analysts expect Immunome to post earnings of ($0.64) per share and revenue of $0.7850 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 3:00 PM ET.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). Immunome had a negative return on equity of 57.61% and a negative net margin of 1,687.08%. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunome Trading Down 3.0%

NASDAQ:IMNM opened at $20.36 on Monday. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -8.41 and a beta of 2.12. The company’s 50-day moving average is $22.73 and its two-hundred day moving average is $18.18. Immunome has a 12-month low of $5.15 and a 12-month high of $27.65.

Insider Buying and Selling

In other Immunome news, Director Isaac Barchas sold 383,200 shares of the stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the transaction, the director owned 2,031,181 shares of the company’s stock, valued at $44,157,874.94. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Philip Tsai purchased 10,000 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was bought at an average price of $20.49 per share, for a total transaction of $204,900.00. Following the acquisition, the insider owned 43,300 shares in the company, valued at $887,217. The trade was a 30.03% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 69,518 shares of company stock valued at $1,475,508. Insiders own 7.69% of the company’s stock.

Institutional Trading of Immunome

A number of institutional investors and hedge funds have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. boosted its holdings in Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after acquiring an additional 5,003,824 shares during the last quarter. Invesco Ltd. increased its stake in Immunome by 382.1% during the fourth quarter. Invesco Ltd. now owns 270,065 shares of the company’s stock worth $5,801,000 after acquiring an additional 214,049 shares during the last quarter. Virtus Investment Advisers LLC raised its holdings in shares of Immunome by 16.9% in the 4th quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock worth $292,000 after purchasing an additional 1,970 shares during the period. Wellington Management Group LLP raised its holdings in shares of Immunome by 267.8% in the 4th quarter. Wellington Management Group LLP now owns 934,463 shares of the company’s stock worth $20,072,000 after purchasing an additional 680,395 shares during the period. Finally, SummitTX Capital L.P. acquired a new position in shares of Immunome in the 4th quarter valued at about $2,741,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Evercore lifted their price target on shares of Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Lake Street Capital lifted their target price on shares of Immunome from $22.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Thursday, January 22nd. Finally, Craig Hallum increased their price target on Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $33.45.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.